Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 7Adenocarcinoma of Lung 5Neoplasms 4Neuroblastoma 3Neoplasm Metastasis 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Melanoma 2Granuloma, Plasma Cell 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, B-Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive Advanced Tumors 1

Interventions

ceritinib 1Warfarin 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ALK-positive Advanced Tumors × ceritinib × Clear all
NCT02422589 2020-12-19

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Novartis

Phase 1 Completed
33 enrolled

ALK-positive Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡